|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ziegler RG, Anderson WF and Gail MH:
Increasing breast cancer incidence in China: The numbers add up. J
Natl Cancer Inst. 100:1339–1341. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yue W, Yager JD, Wang JP, Jupe ER and
Santen RJ: Estrogen receptor-dependent and independent mechanisms
of breast cancer carcinogenesis. Steroids. 78:161–170. 2013.
View Article : Google Scholar
|
|
4
|
Mosselman S, Polman J and Dijkema R: ER
beta: Identification and characterization of a novel human estrogen
receptor. FEBS Lett. 392:49–53. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Williams C and Lin CY: Oestrogen receptors
in breast cancer: Basic mechanisms and clinical implications. E
Cancer Med Sci. 7:3702013.
|
|
6
|
Skliris GP, Munot K, Bell SM, Carder PJ,
Lane S, Horgan K, Lansdown MR, Parkes AT, Hanby AM, Markham AF, et
al: Reduced expression of oestrogen receptor beta in invasive
breast cancer and its re-expression using DNA methyl transferase
inhibitors in a cell line model. J Pathol. 201:213–220. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Han SJ, Guo QQ, Wang T, Wang YX, Zhang YX,
Liu F, Luo YX, Zhang J, Wang YL, Yan YX, et al: Prognostic
significance of interactions between ER alpha and ER beta and lymph
node status in breast cancer cases. Asian Pac J Cancer Prev.
14:6081–6084. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Platet N, Cathiard AM, Gleizes M and
Garcia M: Estrogens and their receptors in breast cancer
progression: A dual role in cancer proliferation and invasion. Crit
Rev Oncol Hematol. 51:55–67. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pettersson K, Delaunay F and Gustafsson
JA: Estrogen receptor beta acts as a dominant regulator of estrogen
signaling. Oncogene. 19:4970–4978. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nilsson S, Mäkelä S, Treuter E, Tujague M,
Thomsen J, Andersson G, Enmark E, Pettersson K, Warner M and
Gustafsson JA: Mechanisms of estrogen action. Physiol Rev.
81:1535–1565. 2001.PubMed/NCBI
|
|
11
|
Fuqua SA, Schiff R, Parra I, Moore JT,
Mohsin SK, Osborne CK, Clark GM and Allred DC: Estrogen receptor
beta protein in human breast cancer: Correlation with clinical
tumor parameters. Cancer Res. 63:2434–2439. 2003.PubMed/NCBI
|
|
12
|
O'Neill PA, Davies MP, Shaaban AM, Innes
H, Torevell A, Sibson DR and Foster CS: Wild-type oestrogen
receptor beta (ERbeta1) mRNA and protein expression in
Tamoxifen-treated post-menopausal breast cancers. Br J Cancer.
91:1694–1702. 2004.PubMed/NCBI
|
|
13
|
Kerdivel G, Flouriot G and Pakdel F:
Modulation of estrogen receptor alpha activity and expression
during breast cancer progression. Vitam Horm. 93:135–160. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Stassi G, Todaro M, Zerilli M,
Ricci-Vitiani L, Di Liberto D, Patti M, Florena A, Di Gaudio F, Di
Gesù G and De Maria R: Thyroid cancer resistance to
chemotherapeutic drugs via autocrine production of interleukin-4
and interleukin-10. Cancer Res. 63:6784–6790. 2003.PubMed/NCBI
|
|
15
|
Mahmoud SM, Paish EC, Powe DG, Macmillan
RD, Grainge MJ, Lee AH, Ellis IO and Green AR: Tumor-infiltrating
CD8+ lymphocytes predict clinical outcome in breast
cancer. J Clin Oncol. 29:1949–1955. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nagai S and Toi M: Interleukin-4 and
breast cancer. Breast Cancer. 7:181–186. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kmieciak M, Payne KK, Idowu MO, Grimes MM,
Graham L, Ascierto ML, Wang E, Wang XY, Bear HD and Manjili MH:
Tumor escape and progression of HER-2/neu negative breast cancer
under immune pressure. J Transl Med. 9:352011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen C, Guo L, Shi M, Hu M, Hu M, Yu M,
Wang T, Song L, Shen B, Qian L, et al: Modulation of IFN-γ receptor
1 expression by AP-2α influences IFN-γ sensitivity of cancer cells.
Am J Pathol. 180:661–671. 2012. View Article : Google Scholar
|
|
19
|
García-Tuñón I, Ricote M, Ruiz AA, Fraile
B, Paniagua R and Royuela M: Influence of IFN-gamma and its
receptors in human breast cancer. BMC Cancer. 7:1582007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Obiri NI, Siegel JP, Varricchio F and Puri
RK: Expression of high-affinity IL-4 receptors on human melanoma,
ovarian and breast carcinoma cells. Clin Exp Immunol. 95:148–155.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Obiri NI, Hillman GG, Haas GP, Sud S and
Puri RK: Expression of high affinity interleukin-4 receptors on
human renal cell carcinoma cells and inhibition of tumor cell
growth in vitro by interleukin-4. J Clin Invest. 91:88–93. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Varricchio F, Obiri NI, Haas GP and Puri
RK: Immunostaining of interleukin-4 receptor on human renal cell
carcinoma. Lymphokine Cytokine Res. 12:465–469. 1993.PubMed/NCBI
|
|
23
|
Toi M, Bicknell R and Harris AL:
Inhibition of colon and breast carcinoma cell growth by
interleukin-4. Cancer Res. 52:275–279. 1992.PubMed/NCBI
|
|
24
|
Todaro M, Lombardo Y, Francipane MG, Alea
MP, Cammareri P, Iovino F, Di Stefano AB, Di Bernardo C, Agrusa A,
Condorelli G, et al: Apoptosis resistance in epithelial tumors is
mediated by tumor-cell-derived interleukin-4. Cell Death Differ.
15:762–772. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Prokopchuk O, Liu Y, Henne-Bruns D and
Kornmann M: Interleukin-4 enhances proliferation of human
pancreatic cancer cells: Evidence for autocrine and paracrine
actions. Br J Cancer. 92:921–928. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Conticello C, Pedini F, Zeuner A, Patti M,
Zerilli M, Stassi G, Messina A, Peschle C and De Maria R: IL-4
protects tumor cells from anti-CD95 and chemotherapeutic agents via
up-regulation of antiapoptotic proteins. J Immunol. 172:5467–5477.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Todaro M, Zerilli M, Ricci-Vitiani L, Bini
M, Perez Alea M, Maria Florena A, Miceli L, Condorelli G, Bonventre
S, Di Gesù G, et al: Autocrine production of interleukin-4 and
interleukin-10 is required for survival and growth of thyroid
cancer cells. Cancer Res. 66:1491–1499. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Turgeon C, Gingras S, Carrière MC, Blais
Y, Labrie F and Simard J: Regulation of sex steroid formation by
interleukin-4 and interleukin-6 in breast cancer cells. J Steroid
Biochem Mol Biol. 65:151–162. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hong CC, Yao S, McCann SE, Dolnick RY,
Wallace PK, Gong Z, Quan L, Lee KP, Evans SS, Repasky EA, et al:
Pretreatment levels of circulating Th1 and Th2 cytokines, and their
ratios, are associated with ER-negative and triple negative breast
cancers. Breast Cancer Res Treat. 139:477–488. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li HZ, Wang Y, Gao Y, Shao J, Zhao XL,
Deng WM, Liu YX, Yang J and Yao Z: Effects of raf kinase inhibitor
protein expression on metastasis and progression of human
epithelial ovarian cancer. Mol Cancer Res. 6:917–928. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Huang B, Omoto Y, Iwase H, Yamashita H,
Toyama T, Coombes RC, Filipovic A, Warner M and Gustafsson JÅ:
Differential expression of estrogen receptor α, β1, and β2 in
lobular and ductal breast cancer. Proc Natl Acad Sci USA.
111:1933–1938. 2014. View Article : Google Scholar
|
|
32
|
Murphy LC and Leygue E: The role of
estrogen receptor-β in breast cancer. Semin Reprod Med. 30:5–13.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tonetti DA, Rubenstein R, DeLeon M, Zhao
H, Pappas SG, Bentrem DJ, Chen B, Constantinou A and Craig Jordan
V: Stable transfection of an estrogen receptor beta cDNA isoform
into MDA-MB-231 breast cancer cells. J Steroid Biochem Mol Biol.
87:47–55. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hou YF, Yuan ST, Li HC, Wu J, Lu JS, Liu
G, Lu LJ, Shen ZZ, Ding J and Shao ZM: ERbeta exerts multiple
stimulative effects on human breast carcinoma cells. Oncogene.
23:5799–5806. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fox EM, Davis RJ and Shupnik MA: ERbeta in
breast cancer -onlooker, passive player, or active protector?
Steroids. 73:1039–1051. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Skliris GP, Leygue E, Curtis-Snell L,
Watson PH and Murphy LC: Expression of oestrogen receptor-beta in
oestrogen receptor-alpha negative human breast tumours. Br J
Cancer. 95:616–626. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Monroe DG, Secreto FJ, Subramaniam M, Getz
BJ, Khosla S and Spelsberg TC: Estrogen receptor alpha and beta
heterodimers exert unique effects on estrogen- and
tamoxifen-dependent gene expression in human U2OS osteosarcoma
cells. Mol Endocrinol. 19:1555–1568. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Weitsman GE, Skliris G, Ung K, Peng B,
Younes M, Watson PH and Murphy LC: Assessment of multiple different
estrogen receptor-beta antibodies for their ability to
immunoprecipitate under chromatin immunoprecipitation conditions.
Breast Cancer Res Treat. 100:23–31. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Jonsson P, Katchy A and Williams C:
Support of a bi-faceted role of estrogen receptor β (ERβ) in
ERα-positive breast cancer cells. Endocr Relat Cancer. 21:143–160.
2014. View Article : Google Scholar :
|
|
40
|
Chavey C, Bibeau F, Gourgou-Bourgade S,
Burlinchon S, Boissière F, Laune D, Roques S and Lazennec G:
Oestrogen receptor negative breast cancers exhibit high cytokine
content. Breast Cancer Res. 9:R152007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kidd P: Th1/Th2 balance: The hypothesis,
its limitations, and implications for health and disease. Altern
Med Rev. 8:223–246. 2003.PubMed/NCBI
|
|
42
|
Hartman J, Lindberg K, Morani A, Inzunza
J, Ström A and Gustafsson JA: Estrogen receptor beta inhibits
angiogenesis and growth of T47D breast cancer xenografts. Cancer
Res. 66:11207–11213. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Brueggemeier RW, Hackett JC and Diaz-Cruz
ES: Aromatase inhibitors in the treatment of breast cancer. Endocr
Rev. 26:331–345. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Gutierrez MC, Detre S, Johnston S, Mohsin
SK, Shou J, Allred DC, Schiff R, Osborne CK and Dowsett M:
Molecular changes in tamoxifen-resistant breast cancer:
Relationship between estrogen receptor, HER-2, and p38
mitogen-activated protein kinase. J Clin Oncol. 23:2469–2476. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Gallo D, De Stefano I, Grazia Prisco M,
Scambia G and Ferrandina G: Estrogen receptor beta in cancer: An
attractive target for therapy. Curr Pharm Des. 18:2734–2757. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Honma N, Horii R, Iwase T, Saji S, Younes
M, Takubo K, Matsuura M, Ito Y, Akiyama F and Sakamoto G: Clinical
importance of estrogen receptor-beta evaluation in breast cancer
patients treated with adjuvant tamoxifen therapy. J Clin Oncol.
26:3727–3734. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Pitta CA, Papageorgis P, Charalambous C
and Constantinou AI: Reversal of ER-β silencing by chromatin
modifying agents overrides acquired tamoxifen resistance. Cancer
Lett. 337:167–176. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Razandi M, Pedram A, Jordan VC, Fuqua S
and Levin ER: Tamoxifen regulates cell fate through mitochondrial
estrogen receptor beta in breast cancer. Oncogene. 32:3274–3285.
2013. View Article : Google Scholar
|
